Wellington Management

AssetWatch is a leading provider of proactive and predictive maintenance solutions focused on eliminating unplanned downtime for global manufacturers. The company specializes in end-to-end remote condition monitoring, utilizing a network of wireless sensors to collect critical machine health data, which is then analyzed through cloud-based software. Leveraging machine learning algorithms and insights from condition monitoring engineers, AssetWatch transforms data into actionable intelligence, enabling manufacturers to adopt a proactive maintenance culture. Their approach enhances the predictive maintenance process with expert prescriptive recommendations that go beyond standard evaluations, thereby supporting organizations in shifting from reactive to proactive maintenance and reliability strategies.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

Lumafield is a company that specializes in industrial computed tomography (CT) solutions aimed at non-destructive testing and inspection for engineers. Its flagship product, the Neptune X-ray CT scanner, offers detailed imaging capabilities that allow engineers to analyze internal structures and identify defects in various materials. Complementing this hardware is the Voyager software platform, which provides cloud-based, AI-powered analysis, facilitating automated inspections and collaborative tools for engineers. Additionally, Lumafield's Triton system is engineered for high-speed scanning, catering to high-volume manufacturing processes. The company’s solutions are utilized across multiple industries, including aerospace, automotive, electronics, and medical devices, ultimately enhancing product quality and reliability throughout the development process.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics aimed at treating acute and chronic pain. The company specializes in creating products that address the limitations of existing pain management therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Its lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for the generation and conduction of pain signals. By targeting this specific channel, SiteOne Therapeutics aims to provide more effective and safer pain relief options for healthcare professionals and their patients, particularly in the treatment of neuropathic pain.

MBX Biosciences, Inc. is a biotechnology company founded in 2018 and based in Carmel, Indiana. The company specializes in developing therapeutics for rare endocrine disorders, focusing on conditions that currently lack effective treatments. MBX Biosciences aims to discover, develop, and commercialize first-in-class therapies, particularly peptides designed to address endocrine genetic diseases that affect glandular hormone production and the body’s chemical messaging systems.

Scorpion Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on advancing precision oncology for cancer treatment. Founded in 2020, the company specializes in developing targeted small-molecule drugs that address validated cancer targets, as well as previously undruggable and novel targets. Scorpion Therapeutics utilizes an integrated approach that combines target discovery, medicinal chemistry, and translational medicine to create a diverse pipeline of optimized compounds. By leveraging its precision medicine platform, the company aims to enhance the efficacy of cancer therapies and expand treatment options for patients, ultimately striving to overcome the limitations of existing cancer treatments.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Obsidian Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing next-generation cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Its innovative approach utilizes pharmacologic operating systems that enable precise control over protein activity within cells. This technology allows for the creation of adoptive cell therapies with novel functionalities, which can be regulated by treating physicians using simple and safe orally active medications. Through these advancements, Obsidian Therapeutics seeks to improve upon existing cell therapies and expand treatment options for a broader patient demographic.

Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for idiopathic pulmonary fibrosis (IPF) and other serious respiratory conditions. Headquartered in Seattle, Washington, with an additional office in San Diego, the company specializes in an inhaled formulation of pirfenidone, known as AP01. This formulation aims to enhance the amount of medication that reaches the lungs while minimizing side effects associated with oral treatments. Established in 2011, Avalyn Pharma is dedicated to improving care and outcomes for patients with severe respiratory diseases through its advanced therapeutic pipeline and novel inhaled therapeutics. Initially named Genoa Pharmaceuticals, the company rebranded to its current name in July 2017.

SKIMS is a brand focused on creating innovative underwear, loungewear, and shapewear designed to enhance body shape. The company manufactures and retails a diverse array of products, including bodysuits, shapewear, and various styles of underwear. SKIMS offers a broad selection of colors and sizes to cater to different body types, ensuring that women receive both the support and coverage they need. By prioritizing inclusivity and functionality, SKIMS aims to address the diverse needs of its customers in the intimate apparel market.

Musinsa Co., Ltd. is a fashion-focused company based in Seoul, South Korea, established in 2012. It operates both online and offline, offering a diverse range of products that include apparel, footwear, accessories, cosmetics, and more. Musinsa serves as a platform for various brands, including subculture, national, and global sports brands, providing customers with curated content, styling pictorials, and information on fashion trends. The company emphasizes customer engagement by allowing users to interact with brands and access personalized curation and storytelling. Additionally, Musinsa publishes an online fashion web magazine that showcases product information and brand highlights, further enriching the fashion culture and consumption experience in the Korean market.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

Meati Foods is a consumer goods company based in Boulder, Colorado, that specializes in the production and sale of fungi-based meat alternatives. Founded in 2016, the company aims to provide nutrient-dense, plant-based options that serve as sustainable substitutes for traditional meat. Meati's products are crafted using proprietary fermentation technologies and are minimally processed, ensuring they are free from common allergens. The company is committed to offering vegan food choices that are accessible and enjoyable for a diverse range of consumers.

Juspay Technologies Pvt Ltd. is a Bengaluru-based company, founded in 2012, that specializes in mobile payment solutions. It offers a suite of products, including JUSPAY SAFE, a mobile payments browser, and EXPRESS CHECKOUT, which enhances payment gateway performance. The company's online platform serves as a software-as-a-service layer over existing payment gateways, streamlining integration and improving the management of various payment options. This enables users to conduct electronic transactions securely and efficiently, catering to the evolving needs of mobile-based payments.

Course Hero operates as an online learning platform dedicated to providing study resources for students and educators. Founded in 2006 and based in Redwood City, California, the company offers a range of materials including lecture notes, study guides, textbook help, practice problems, exams, and video lectures from universities across the United States and internationally. Course Hero's platform is subscription-based and includes an educator platform for distributing materials and publishing content. Additionally, it features a flashcards application and access to expert tutors who assist students with their queries. The company was previously known as TheCollegeFreeway.

Teya is a comprehensive solution tailored for small and growing businesses, offering a suite of services that facilitate efficient management and growth. The company specializes in payment processing, providing fast and secure transaction capabilities, along with cloud-native business management software. Teya's offerings include issuer payment processing and cash advance services, which assist merchants in enhancing their operations. With a commitment to supporting over 300,000 business owners, Teya enables them to effectively manage their businesses and fosters a positive experience in their entrepreneurial journey.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Sundae is a residential real estate marketplace designed to assist homeowners in selling their properties off-market. The company's platform caters specifically to individuals looking to sell dated or damaged homes without the hassle of traditional real estate processes, which often involve repairs, cleaning, and showings. Sundae allows sellers to list their homes as-is and on their own timeline, streamlining the selling experience. By connecting homeowners with a broad network of local investors, Sundae ensures that sellers receive competitive off-market prices for their properties, thus providing a fair alternative to conventional home sales.

Lendbuzz, Inc. is a Boston-based company that operates an innovative car financing platform aimed at individuals with limited or no credit history, such as international students, foreign professionals, and expatriates. Founded in 2015, Lendbuzz uses machine learning algorithms and proprietary technology to assess the creditworthiness of consumers who are typically underserved by traditional financial institutions. By evaluating background information, including employment and educational history, the platform provides tailored car loans and financing solutions with favorable terms and low-interest rates. Lendbuzz partners with auto dealerships to enhance their offerings, allowing them to serve a more diverse clientele and close additional business opportunities. The company emphasizes a streamlined documentation process, making it easier for clients to access and manage their loans.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Cityblock Health, Inc., established in 2017 and headquartered in Brooklyn, New York, operates a personalized health system tailored to meet the unmet health and social needs of Medicaid and Medicare populations. The company's online platform offers integrated primary care, behavioral health, and virtual care services, along with a tool called Commons for communication, information sharing, and task management. Cityblock's model focuses on upstream investment in highly personalized, prevention-oriented care, aiming to improve outcomes and reduce costs. It partners with community-based organizations to deliver care, enabling clinicians to provide personalized care for each member. During the COVID-19 pandemic, Cityblock developed a model to help identify high-risk members within organizations.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Cityblock Health, Inc., established in 2017 and headquartered in Brooklyn, New York, operates a personalized health system tailored to meet the unmet health and social needs of Medicaid and Medicare populations. The company's online platform offers integrated primary care, behavioral health, and virtual care services, along with a tool called Commons for communication, information sharing, and task management. Cityblock's model focuses on upstream investment in highly personalized, prevention-oriented care, aiming to improve outcomes and reduce costs. It partners with community-based organizations to deliver care, enabling clinicians to provide personalized care for each member. During the COVID-19 pandemic, Cityblock developed a model to help identify high-risk members within organizations.

Edgewise Therapeutics, founded in 2017 and based in Boulder, Colorado, is a clinical-stage biopharmaceutical company dedicated to developing precision medicine therapies for severe, rare muscle disorders. The company's core expertise lies in muscle biology and small molecule engineering, which it employs through its proprietary drug discovery platform. This platform uses custom-built systems to measure integrated muscle function, enabling the identification of small molecule therapies targeting key proteins in muscle tissue. Edgewise's pipeline focuses on addressing genetically defined muscle disorders such as Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophies.

Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. By simplifying banking processes and providing user-friendly tools, Current aims to empower users to build a secure financial future. With backing from prominent investors, Current continues to innovate in the financial technology space, striving to meet the diverse needs of its customer base through modern banking solutions.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, enabling the production of functional proteins in the bloodstream. Freeline's pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, the company offers expertise in CMC process development, analytics, and AAV technologies.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Generation Bio Co. is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies aimed at treating both rare and prevalent diseases. Founded in 2016 and formerly known as Torus Therapeutics, the company focuses on creating durable and redosable treatments for conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs a proprietary platform that utilizes closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) to achieve targeted delivery of genetic materials across various tissues. This approach is designed to enhance treatment efficacy while expanding access to therapies for rare diseases and addressing more common conditions through scalable manufacturing processes.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Atreca, Inc. is a biopharmaceutical company focused on the discovery and development of antibody-based immunotherapeutics for various solid tumor types. Founded in 2010 and headquartered in South San Francisco, California, Atreca utilizes a unique platform to identify antibodies produced during immune responses, facilitating the development of novel therapies without prior knowledge of antigens. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, targeting a range of cancers including ovarian, non-small cell lung, colorectal, and breast cancer. The company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to explore antigenic targets for select antibodies with potential applications in oncology.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Nightstar Therapeutics is a clinical-stage gene therapy company based in London, United Kingdom, specializing in the development of innovative one-time treatments for rare inherited retinal diseases. The company is advancing several product candidates, including its lead candidate NSR-REP1, which is in phase 3 clinical development for choroideremia. Additionally, Nightstar is working on NSR-RPGR, currently in phase 2/3 trials for X-linked retinitis pigmentosa, as well as NSR-BEST1. The company is also developing NSR-ABCA4, which is in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address significant unmet medical needs in the field of retinal disorders.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

The Trade Desk, Inc. is a technology company that operates a self-service cloud-based platform designed for advertisers and advertising agencies. Founded in 2009 and headquartered in Ventura, California, the company enables users to create, manage, and optimize data-driven digital advertising campaigns across a variety of formats, including display, video, audio, native, and social. Its platform supports multiple devices, such as computers, mobile devices, and connected TVs. By leveraging data analytics, The Trade Desk helps clients enhance the effectiveness of their advertising efforts. The company generates revenue through fees that are based on a percentage of its clients' advertising expenditures.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Rubicon Global Holdings LLC is a technology company that specializes in cloud-based waste and recycling solutions for businesses, governments, and nonprofits. Founded in 2008 and headquartered in Atlanta, Georgia, Rubicon operates a digital marketplace and offers a suite of software-as-a-service products aimed at enhancing waste management and recycling efforts. The company provides various recycling programs, including services for cardboard, plastic, paper, metal, glass, electronics, and organics, as well as single stream recycling solutions. One of its notable offerings is RUBICONSmartCity, which assists municipal governments in optimizing waste and recycling operations while transforming their fleets into data collection centers to improve quality of life and government services through data analytics. Rubicon serves a global customer base and maintains core teams in several U.S. cities, including New York and San Francisco. The company is committed to driving environmental innovation and helping its partners achieve sustainability goals by finding economic value in waste streams.

TabbedOut puts you in control of your tab at bars and restaurants. Say goodbye to end-of-night bar lines, and flagging down your server when you’re ready to settle the bill. Never leave your card at the bar again! TabbedOut is easier and more secure than handing over your credit card to a stranger. Open a tab, view the running total, and pay for it instantly (and securely) all from your phone. You can even split your tab among friends, post to Facebook or Twitter to let your friends know where you’re dining, send a positive or negative review of your experience, and get offers sent from your favorite venue straight to your phone. TabbedOut takes the hassle out of dining out for good. We are adding new locations every day, so check in often on the locations screen. Don’t see your favorite bar or restaurant on the list? Let us know! Tweet at or Facebook us at @tabbedout. For merchants: TabbedOut is the premier marketing and analytics platform built exclusively for the hospitality industry and powered by mobile payments. We allow our merchants real time insight into their customers through our proprietary software system that tracks spending habits, product preferences, customer feedback and loyalty rewards. Best of all, TabbedOut allows you, the merchant, to accept mobile payments integrated into your POS system. Finally, POS systems and mobile payments meet customer marketing and rewards in real time. That’s the power of TabbedOut! Free to download and no hidden fees.

Harry's Inc., established in 2012 and headquartered in New York, specializes in manufacturing and selling men's grooming products. The company produces a range of shaving items including razors, creams, kits, and face care products. Harry's operates an online platform where consumers can purchase these products individually or via a subscription service for convenient access to their grooming essentials.

Oscar Health is a health insurance company based in New York, founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser. It specializes in offering individual and family health insurance plans, Medicare Advantage programs for seniors, and small group products. Oscar Health aims to enhance the healthcare experience by leveraging technology, design, and data to make services more accessible and user-friendly. The company primarily serves individuals, couples, and families who do not receive employer-sponsored health insurance in select states, including New York, New Jersey, California, and Texas. In addition to traditional insurance offerings, Oscar provides virtual care, doctor support, and appointment scheduling, emphasizing a comprehensive approach to healthcare management.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Powa Technologies is an international commerce specialist based in London, United Kingdom, that focuses on integrating physical and digital retail experiences. The company offers a suite of technologies designed to enhance e-commerce, including PowaTag, a mobile application that facilitates payments through codes that can be applied to various marketing media such as billboards and advertisements. In addition to PowaTag, Powa Technologies provides several other products, including PowaWeb, powaPos, and PowaPIN, which collectively support the development of scalable online shops and enable an agile e-commerce environment. Established in 2007, Powa Technologies operates as a subsidiary of SuperCom Ltd.

The Honest Company, Inc. is a consumer products firm based in Santa Monica, California, established in 2011. It specializes in designing and manufacturing a diverse range of eco-friendly and affordable products aimed at families and homes. The company's offerings include bundles for babies, bath and body care, cleaning supplies, and health and wellness products. Prominent items in their portfolio consist of eco-friendly diapers and wipes, skincare products, household cleaners, and organic nutritional supplements. The Honest Company operates through both retail and digital channels, ensuring broad accessibility for consumers. Its revenue is primarily driven by the sale of diapers and wipes, emphasizing the brand's commitment to convenience and sustainability.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Datalogix is a prominent company specializing in connecting digital media with offline purchasing data, enabling marketers to enhance the effectiveness and measurability of their advertising efforts. The company serves more than half of the top 100 consumer marketers and manages the DLX Platform, which encompasses over $1 trillion in consumer spending and supports campaigns for a significant majority of online media companies. Datalogix's DLX ROI is becoming a standard for measuring the impact of digital media on offline sales. Additionally, the company provides predictive analytics for direct mail and integrated media solutions through the DLX Net. Its expertise covers various consumer sectors, including retail, consumer packaged goods, automotive, telecommunications, travel, and financial services. Headquartered in Colorado, Datalogix has established offices in key cities such as New York City, San Francisco, Boston, Chicago, Detroit, and London.

Malauzai Software, Inc., established in 2009 and headquartered in Austin, Texas, specializes in developing mobile and internet banking solutions tailored for community financial institutions. The company offers a suite of SmartApps, SmartwebApps, and SmartwearApps, catering to consumers, small businesses, and employees, enabling them to manage their financial transactions across various devices. Malauzai's flagship product, the MOX enterprise platform, streamlines management of these solutions on a single platform. The company's products aim to enhance the customer experience and increase value for financial institutions, focusing primarily on community banks and credit unions. Since 2018, Malauzai has operated as a subsidiary of Finastra Group Holdings Limited.

SensAble Technologies, Inc. specializes in the development of force-feedback haptic devices and touch-enabled 3D modeling software solutions. The company offers a range of products, including FreeForm Modeling Systems for medical and dental applications, product design, and digital content creation, as well as The SensAble Dental Lab System for scanning and 3D fabrication. Its PHANTOM Haptic Devices provide force feedback and 3D navigation, while the OpenHaptics software toolkit enables the development of haptic applications. SensAble serves diverse industries such as automotive, dental, fine arts, gaming, and medical, with applications in product design, surgical simulation, and robotic research. Founded in 1993 and based in Woburn, Massachusetts, the company also maintains a sales office in Tokyo, Japan.